236 related articles for article (PubMed ID: 32782240)
21. Prognostic Impact of Cytogenetic Abnormalities in Multiple Myeloma: A Retrospective Analysis of 229 Patients.
Jian Y; Chen X; Zhou H; Zhu W; Liu N; Geng C; Chen W
Medicine (Baltimore); 2016 May; 95(19):e3521. PubMed ID: 27175647
[TBL] [Abstract][Full Text] [Related]
22. Distinct predictive impact of FISH abnormality in proteasome inhibitors and immunomodulatory agents response: redefining high-risk multiple myeloma in Asian patients.
Byun JM; Shin DY; Hong J; Kim I; Kim HK; Lee DS; Koh Y; Yoon SS
Cancer Med; 2018 Mar; 7(3):831-841. PubMed ID: 29380550
[TBL] [Abstract][Full Text] [Related]
23. Utilization of novel systemic therapies for multiple myeloma: A retrospective study of front-line regimens using the SEER-Medicare data.
Goto D; Khairnar R; Yared JA; Yong C; Romanus D; Onukwugha E; Slejko JF
Cancer Med; 2020 Jan; 9(2):626-639. PubMed ID: 31801177
[TBL] [Abstract][Full Text] [Related]
24. Outcomes of primary refractory multiple myeloma and the impact of novel therapies.
Majithia N; Vincent Rajkumar S; Lacy MQ; Buadi FK; Dispenzieri A; Gertz MA; Hayman SR; Dingli D; Kapoor P; Hwa L; Lust JA; Russell SJ; Go RS; Kyle RA; Kumar SK
Am J Hematol; 2015 Nov; 90(11):981-5. PubMed ID: 26214732
[TBL] [Abstract][Full Text] [Related]
25. [Cytogenetic Abnormalities and Outcomes of 117 Patients with Multiple Myeloma Detected by FISH].
Zhai B; Zou DD; Yan JJ; Wang N; Wang LL; Zhu HL; Huang WR; Yu L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Feb; 24(1):127-30. PubMed ID: 26913408
[TBL] [Abstract][Full Text] [Related]
26. Detection of chromosome 13q deletions and IgH translocations in patients with multiple myeloma by FISH: comparison with karyotype analysis.
Chang H; Li D; Zhuang L; Nie E; Bouman D; Stewart AK; Chun K
Leuk Lymphoma; 2004 May; 45(5):965-9. PubMed ID: 15291356
[TBL] [Abstract][Full Text] [Related]
27. Infection risk with immunomodulatory and proteasome inhibitor-based therapies across treatment phases for multiple myeloma: A systematic review and meta-analysis.
Teh BW; Harrison SJ; Worth LJ; Thursky KA; Slavin MA
Eur J Cancer; 2016 Nov; 67():21-37. PubMed ID: 27592069
[TBL] [Abstract][Full Text] [Related]
28. [Treatment strategies for multiple myeloma based on molecular pathogenesis].
Furukawa Y
Rinsho Ketsueki; 2022; 63(9):1167-1179. PubMed ID: 36198542
[TBL] [Abstract][Full Text] [Related]
29. Racial differences in primary cytogenetic abnormalities in multiple myeloma: a multi-center study.
Greenberg AJ; Philip S; Paner A; Velinova S; Badros A; Catchatourian R; Ketterling R; Kyle RA; Kumar S; Vachon CM; Rajkumar SV
Blood Cancer J; 2015 Jan; 5(1):e271. PubMed ID: 25555162
[TBL] [Abstract][Full Text] [Related]
30. Treatment patterns and outcomes among nontransplant newly diagnosed multiple myeloma patients in Spain.
Hernández-Rivas JÁ; Arnao M; Arguiñano Pérez JM; Rubio A; García EG; de Miguel D; Cherepanov D; Romanus D; Verleger K; Johnson C; Corman SL; Grande M; Persona EP
Future Oncol; 2021 Sep; 17(26):3465-3476. PubMed ID: 34342494
[TBL] [Abstract][Full Text] [Related]
31. [Not Available].
Hitz F
Praxis (Bern 1994); 2016; 105(21):1255-1260. PubMed ID: 28573955
[No Abstract] [Full Text] [Related]
32. Observation on frequency & clinico-pathological significance of various cytogenetic risk groups in multiple myeloma: an experience from India.
Kadam Amare PS; Jain H; Nikalje S; Sengar M; Menon H; Inamdar N; Subramanian PG; Gujral S; Shet T; Epari S; Nair R
Indian J Med Res; 2016 Oct; 144(4):536-543. PubMed ID: 28256461
[TBL] [Abstract][Full Text] [Related]
33. Clinical and biologic implications of recurrent genomic aberrations in myeloma.
Fonseca R; Blood E; Rue M; Harrington D; Oken MM; Kyle RA; Dewald GW; Van Ness B; Van Wier SA; Henderson KJ; Bailey RJ; Greipp PR
Blood; 2003 Jun; 101(11):4569-75. PubMed ID: 12576322
[TBL] [Abstract][Full Text] [Related]
34. Cytogenetic Profiling of Myelomas, Association With Complete Blood Count: Study of 180 Patients.
Tarigopula A; Chandrashekar V; Govindasamy P
Lab Med; 2017 Dec; 49(1):68-74. PubMed ID: 29206983
[TBL] [Abstract][Full Text] [Related]
35. Immunomodulatory drugs in the treatment of multiple myeloma.
Abe Y; Ishida T
Jpn J Clin Oncol; 2019 Aug; 49(8):695-702. PubMed ID: 31187860
[TBL] [Abstract][Full Text] [Related]
36. The impact of bone marrow fibrosis and JAK2 expression on clinical outcomes in patients with newly diagnosed multiple myeloma treated with immunomodulatory agents and/or proteasome inhibitors.
Paul B; Zhao Y; Loitsch G; Feinberg D; Mathews P; Barak I; Dupuis M; Li Z; Rein L; Wang E; Kang Y
Cancer Med; 2020 Aug; 9(16):5869-5880. PubMed ID: 32628819
[TBL] [Abstract][Full Text] [Related]
37. Recurrent Cytogenetic Abnormalities in Multiple Myeloma.
Chan NC; Chan NP
Methods Mol Biol; 2017; 1541():295-302. PubMed ID: 27910031
[TBL] [Abstract][Full Text] [Related]
38. Development and Validation of a Cytogenetic Prognostic Index Predicting Survival in Multiple Myeloma.
Perrot A; Lauwers-Cances V; Tournay E; Hulin C; Chretien ML; Royer B; Dib M; Decaux O; Jaccard A; Belhadj K; Brechignac S; Fontan J; Voillat L; Demarquette H; Collet P; Rodon P; Sohn C; Lifermann F; Orsini-Piocelle F; Richez V; Mohty M; Macro M; Minvielle S; Moreau P; Leleu X; Facon T; Attal M; Avet-Loiseau H; Corre J
J Clin Oncol; 2019 Jul; 37(19):1657-1665. PubMed ID: 31091136
[TBL] [Abstract][Full Text] [Related]
39. Ixazomib-based regimens for relapsed/refractory multiple myeloma: are real-world data compatible with clinical trial outcomes? A multi-site Israeli registry study.
Cohen YC; Magen H; Lavi N; Gatt ME; Chubar E; Horowitz N; Kreiniz N; Tadmor T; Trestman S; Vitkon R; Rouvio O; Shvetz O; Shaulov A; Ziv-Baran T; Avivi I
Ann Hematol; 2020 Jun; 99(6):1273-1281. PubMed ID: 32193630
[TBL] [Abstract][Full Text] [Related]
40. Trends in the multiple myeloma treatment landscape and survival: a U.S. analysis using 2011-2019 oncology clinic electronic health record data.
Braunlin M; Belani R; Buchanan J; Wheeling T; Kim C
Leuk Lymphoma; 2021 Feb; 62(2):377-386. PubMed ID: 33026271
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]